Sanguinarine (Benzophenanthridine Alkaloid · Antimicrobial · Oral Health History · Antiproliferative)
| Compound | Sanguinarine (Pseudochelerythrine) |
| Chemical class | Alkaloid — Isoquinoline / Benzophenanthridine (Quaternary ammonium; red alkaloid) |
| CAS | 2447-54-3 |
| Primary source | Sanguinaria canadensis (bloodroot rhizome), Chelidonium majus, Macleaya cordata (Plume poppy) |
| Key applications | Antimicrobial; antiplaque (oral health); antiproliferative; topical applications; availability on request |
| Claim strength | Moderate |
| Typical form | Bloodroot extract; sanguinarine isolate; oral health formulations (historical toothpaste) |
| Buy from Herbuno | Request availability and bulk pricing → |
Name origin: From Sanguinaria (bloodroot genus; sanguis = blood in Latin, referring to the bright red latex of bloodroot rhizome). Sanguinarine is a benzophenanthridine alkaloid — a quaternary ammonium salt that exists in equilibrium between a charged iminium form and a neutral pseudobase form at physiological pH. This equilibrium determines its bioavailability and mechanism of action. The red colour of bloodroot latex is due to sanguinarine and related alkaloids. Traditional use: Bloodroot (Sanguinaria canadensis) was used by Native American peoples (Iroquois, Ojibwa) as an emetic, expectorant, and topical treatment for skin conditions including warts and tumours. European settlers adopted bloodroot as a dental and respiratory herb. The escharotic property of concentrated bloodroot preparations (causing tissue destruction) has been exploited in “black salves” marketed for skin cancer removal — a practice strongly condemned by medical authorities as ineffective and dangerous. Commercial history — oral health: Sanguinarine-containing toothpastes (Viadent) were commercially significant in the 1980s–1990s, marketed for anti-plaque activity. However, epidemiological evidence linking Viadent use to oral leukoplakia (a pre-malignant condition) caused product withdrawal in the early 2000s. This remains a significant cautionary example in botanical oral health formulation. Commercial source: Not currently in the Herbuno catalogue. Contact Herbuno for availability assessment.
Evidence for Sanguinarine Applications
Antimicrobial and anti-plaque: Sanguinarine demonstrates broad-spectrum antimicrobial activity against oral pathogens (Streptococcus mutans, Porphyromonas gingivalis, Actinomyces) at MIC values of 1–8 μg/mL. It is particularly effective at inhibiting bacterial adherence and biofilm formation at sub-MIC concentrations. Multiple clinical trials in the 1980s showed plaque reduction, but the subsequent oral leukoplakia association has significantly moderated enthusiasm. Claim strength: Moderate (clinical anti-plaque evidence; safety concerns moderate the application).
Antiproliferative and pro-apoptotic: Sanguinarine induces apoptosis in cancer cell lines via ROS generation, caspase activation, and DNA intercalation (its quaternary ammonium group allows insertion between DNA base pairs). Selective toxicity to cancer cells relative to normal cells has been reported in some models. Preclinical in vivo data exist for skin, colon, and prostate cancer models. Claim strength: Moderate (preclinical; no clinical oncology data).
Anti-inflammatory: Sanguinarine inhibits NF-κB, COX-2, and lipoxygenase pathways at low micromolar concentrations. Relevant for topical anti-inflammatory applications. The anti-inflammatory and antimicrobial combination makes sanguinarine theoretically useful for inflammatory gum disease, but the leukoplakia concern limits oral mucosal contact applications. Claim strength: Moderate (in vitro and animal).
Request availability and bulk pricing →
Browse Standardised Extract Powders →
Dosage & Formulator Specification
No safe human oral supplement dose is established given the oral leukoplakia association with prolonged mucosal contact. For antimicrobial applications, sanguinarine has been used at 0.03–0.05% in oral rinses (concentrations used in Viadent products). For topical (non-mucosal) antiproliferative applications, research concentrations of 1–5 μM are effective in vitro — translating to approximately 0.01–0.05% in topical formulations. Formulators should avoid oral mucosal contact formulations with sanguinarine pending clearer safety data. Topical skin applications (outside of the mouth) carry different risk profiles — the black salve context also requires caution given regulatory warnings.
Frequently Asked Questions — Sanguinarine
What is the connection between sanguinarine and oral leukoplakia?
Epidemiological studies in the 1990s–2000s found that long-term users of sanguinarine-containing toothpaste (Viadent) had significantly higher rates of oral leukoplakia — a white mucosal lesion classified as pre-malignant in some cases. The mechanism is believed to involve sanguinarine’s DNA-intercalating and ROS-generating properties at mucosal contact points, causing mucosal dysplasia with repeated long-term exposure. Procter & Gamble (which had acquired Viadent) withdrew the product from the US market by 2006. This is a critical formulation safety precedent: a compound with legitimate antimicrobial activity caused harm when formulated for prolonged mucosal contact.
What is bloodroot black salve and why is it dangerous?
Black salve is a topical preparation containing concentrated bloodroot (sanguinarine) and zinc chloride, marketed as a “natural skin cancer cure.” The preparation causes tissue escharosis (caustic necrosis) — it destroys tissue non-selectively. While it does destroy the surface lesion, it has no selectivity for malignant vs normal tissue, fails to remove subcutaneous tumour extensions, leaves large scars, and delays evidence-based cancer treatment. The FDA has issued multiple warnings against black salve, and deaths from delayed skin cancer treatment have been documented. The escharotic properties of bloodroot are real but the therapeutic application for cancer is unvalidated and dangerous.
Is sanguinarine from Chelidonium the same as from bloodroot?
Chemically identical — sanguinarine from Chelidonium majus (greater celandine) and Sanguinaria canadensis (bloodroot) is the same molecule. Both plants contain sanguinarine alongside other benzophenanthridine alkaloids (chelerythrine, chelirubine in Chelidonium; sanguirubine in bloodroot). The relative ratios of benzophenanthridine alkaloids differ between species. Celandine extract (Herbuno: Chelidonine page) delivers a different alkaloid profile from bloodroot — chelidonine is the primary alkaloid, with sanguinarine as a secondary constituent.
Is sanguinarine safe for topical use outside the mouth?
Topical sanguinarine on intact skin (not mucosal surfaces) carries a different risk profile from oral mucosal use. At low concentrations in topical preparations (0.01–0.05%), sanguinarine is used for antimicrobial and anti-inflammatory skin applications without the leukoplakia concern seen at oral mucosal contact doses. Formulators should avoid concentrated preparations (black salve concentrations) and restrict applications to intact skin — not wounds, mucous membranes, or skin lesions where absorption and cell-level damage could occur. Patch testing is appropriate before large-area application.
Related compounds: Chelidonine, Berberine, Noscapine, Emetine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery